Impressive Results in STAR-LLD Phase 1b Trial for Multiple Myeloma Patients
Friday, 21 June 2024, 12:05
Impressive Results in Phase 1b Trial
All enrolled patients achieved a partial response or better in the STAR-LLD Phase 1b trial conducted by Starton Therapeutics.
Milder Adverse Events
- Less frequent and milder drug-related adverse events were observed during the trial.
This data signifies significant progress in the treatment of multiple myeloma, indicating a promising future for patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.